Myeloma Clinical Trials in Atlanta, Georgia
46 recruitingAtlanta, Georgia
Showing 1–20 of 46 trials
Recruiting
Phase 1
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Multiple Myeloma
AstraZeneca40 enrolled13 locationsNCT07073547
Recruiting
Phase 1
Pilot Imaging Study of Leukemia
Acute Myeloid LeukemiaMyelomaAcute Lymphocytic Leukemia+1 more
University of Oklahoma60 enrolled3 locationsNCT03633955
Recruiting
Phase 3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Multiple MyelomaNewly Diagnosed Multiple Myeloma
GlaxoSmithKline520 enrolled181 locationsNCT06679101
Recruiting
Phase 2
CAR T-cell Therapy in Patients With Renal Dysfunction
Multiple MyelomaAcute Lymphoblastic Leukemia, AdultNon-hodgkin Lymphoma,B Cell
Northside Hospital, Inc.20 enrolled1 locationNCT05909059
Recruiting
Not Applicable
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
Memorial Sloan Kettering Cancer Center180 enrolled8 locationsNCT05640843
Recruiting
Collection of Tissue Samples for Cancer Research
NeoplasmsMultiple MyelomaMyelodysplastic Syndrome+1 more
National Cancer Institute (NCI)5,000 enrolled17 locationsNCT00900198
Recruiting
Phase 3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC400 enrolled39 locationsNCT07258511
Recruiting
Phase 2
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC157 enrolled31 locationsNCT07266441
Recruiting
Phase 1Phase 2
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
National Cancer Institute "Cancer Moonshot Biobank"
Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting
Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
American Society of Clinical Oncology4,200 enrolled174 locationsNCT02693535
Recruiting
Phase 1Phase 2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Plasma Cell Myeloma Refractory
Sanofi258 enrolled28 locationsNCT04643002
Recruiting
Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Multiple Myeloma
European Myeloma Network B.V.1,594 enrolled211 locationsNCT05243797
Recruiting
Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 4
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Multiple Myeloma
Emory University94 enrolled1 locationNCT07101445
Recruiting
Phase 2
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company230 enrolled52 locationsNCT06297226
Recruiting
Phase 2
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Plasma Cell Myeloma
Emory University34 enrolled1 locationNCT05208307
Recruiting
Phase 2
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
Refractory Multiple MyelomaRelapse Multiple Myeloma
Multiple Myeloma Research Consortium300 enrolled13 locationsNCT06171685
Recruiting
Not Applicable
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Bone PainMetastatic Malignant Neoplasm in the BonePlasma Cell Myeloma
University of Southern California100 enrolled9 locationsNCT03858205
Recruiting
Phase 1Phase 2
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Multiple MyelomaNHLRefractory Non-Hodgkin Lymphoma+1 more
Indapta Therapeutics, INC.128 enrolled12 locationsNCT06119685